BHCM
NMRA icon

Brevan Howard Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Brevan Howard Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-97,075
Closed -$189K – 2425
2026
Q1 		$189K Buy
+97,075
New +$252K ﹤0.01% 1914
2025
Q2 		– Sell
-46,254
Closed -$46.3K – 1952
2025
Q1 		$46.3K Sell
46,254
-34,305
-43% -$58.7K ﹤0.01% 1092
2024
Q4 		$854K Buy
+80,559
New +$966K 0.01% 471

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brevan Howard Capital Management's NMRA Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 97,075 shares — an estimated $189K sold.

Brevan Howard Capital Management first reported a position in NMRA in Q4 2024 and held it in 3 quarters. The position peaked at $854K in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 97,075 Neumora Therapeutics shares in Q2 2026, an estimated $189K.
  • Brevan Howard Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and held it in 3 quarters.
  • Brevan Howard Capital Management's Neumora Therapeutics position peaked at $854K in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.